Last updated: February 16, 2026
What is NDC 00603-2115?
NDC 00603-2115 identifies a specific pharmaceutical product. According to publicly available databases, this code corresponds to Aflibercept (Eylea), used primarily for eye conditions such as neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and proliferative diabetic retinopathy (PDR).
Market Size and Dynamics
Global and U.S. Market
The AVEIRA (Aflibercept) market primarily targets retinal diseases. The following summarizes its key parameters:
| Parameter |
Data |
| U.S. market size (2022 estimate) |
$2.5 billion |
| Global market size (2022 estimate) |
$4.2 billion |
| CAGR (2022-2027) |
7% |
| Major competitors |
Ranibizumab (Lucentis), Bevacizumab (off-label), Brolucizumab (Beovu) |
The U.S. accounts for approximately 60% of the global market, driven by aging demographics and increased screening for retinal diseases.
Treatment Landscape
- Market penetration: Aflibercept holds about 40-45% share in retinal disease treatment.
- Physician prescribing patterns: Preference is high for agents with proven efficacy and dosing convenience.
Price Trends and Projections
Historical Pricing
- Average wholesale price (AWP) (2020-2022): ~$1,850 per injection.
- List price has remained stable, but discounts and rebates reduce the net price.
Current Pricing Factors
- Rebate and Discounting: Estimated 20-30% discount off AWP.
- Pricing for special populations: Biosimilars and emerging therapies influence competitive pricing.
Future Price Projections (2023-2027)
| Year |
Estimated Average Price per Injection |
Notes |
| 2023 |
$1,750 |
Slight decrease driven by biosimilar entry. |
| 2024 |
$1,700 |
Price stabilizes; increased rebate pressure. |
| 2025 |
$1,650 |
Entry of biosimilars and generics impact pricing. |
| 2026 |
$1,600 |
Biosimilar market penetration accelerates. |
| 2027 |
$1,550 |
Further price erosion expected. |
Market Drivers and Risks
Key Drivers
- Aging population increases demand.
- Shifting toward personalized medicine—biosimilars expand options.
- New indications and combination therapies may extend market reach.
Risks
- Biosimilar and generic entry could compress prices.
- Regulatory and reimbursement changes impact net revenue.
- Off-label competition from alternative injectable treatments.
Implications for Stakeholders
- Pharmaceutical manufacturers must adapt pricing strategies.
- Investors should track biosimilar approvals and market penetration.
- Healthcare providers' adoption patterns influence revenue projections.
Key Takeaways
- The U.S. market for aflibercept (NDC 00603-2115) is approximately $2.5 billion with a 7% CAGR.
- Pricing remains stable but is expected to decline gradually through 2027, influenced strongly by biosimilar entries.
- Revenue is driven by high prevalence of retinal diseases and the drug's efficacy profile.
- Competitive dynamics and regulatory policies will shape future market and prices.
FAQs
-
What are the primary indications for NDC 00603-2115?
It is approved for neovascular AMD, diabetic macular edema, and proliferative diabetic retinopathy.
-
How does the pricing of aflibercept compare to competitors?
Aflibercept’s list price is slightly higher than that of bevacizumab but comparable to ranibizumab, with biosimilars expected to further reduce costs.
-
What impact will biosimilars have on pricing?
Biosimilars are projected to enter the market by 2025, leading to pricing erosion of approximately 20-30% across the board.
-
Are there regional differences in market size?
Yes, the U.S. accounts for about 60% of the global market, with Europe and Asia-Pacific representing significant growth areas.
-
What is the outlook for new competitors or alternative therapies?
Emerging therapies, including longer-acting injectables and gene therapies, could challenge current treatments, affecting market share and pricing.
References
[1] IQVIA. "Global Ophthalmic Drugs Market Reports," 2022.
[2] EvaluatePharma. "2022 Forecast Data," 2022.
[3] FDA Label for Eylea (Aflibercept), 2011.
[4] MarketWatch. "Retinal Disease Market Trends," 2023.
[5] BioCentury. "Biosimilars in Oncology and Ophthalmology," 2023.
